Infections and inflammatory diseases as risk factors for venous thrombosis

Summary

Inflammation and venous thrombosis are intertwined. Only in the recent 15 years clinical epidemiological studies have focussed on inflammatory or infectious diseases as risk factors for venous thrombosis. Although a few reviews and many case reports or studies on these topic has been written, a review reporting relative or absolute risks for venous thrombosis has not been published yet. We performed a systematic review using Medline, Pubmed and Embase and found 31 eligible articles. Inflammatory bowel disease, ANCA-associated vasculitis, infections in general and more specifically, human immunodeficiency virus, pneumonia and urinary tract infections are associated with an increased risk of venous thrombosis.

Keywords

Venous thrombosis - inflammatory diseases - infections - risk factors

• References

• 1 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
• 2 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824-833.
• 3 Cermak J, Key NS, Bach RR. et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
• 4 van der Poll T, Büller HR, ten Cate H. et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
• 5 Tabib A, Greenland T, Mercier I. et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet 1992; 340: 730.
• 6 Abgueguen P, Delbos V, Chennebault JM. et al. Vascular thrombosis and acute cy-tomegalovirus infection in immunocompetent patients: report of 2 cases and literature review. Clinical Infectious Diseases 2003; 36: E134-139.
• 7 Wells G, Shea B, OConnell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 8 Seriolo B, Accardo S, Garnero A. et al. Anticardiolipin antibodies, free protein S levels and thrombosis: a survey in a selected population of rheumatoid arthritis patients. Rheumatology 1999; 38: 675-678.
• 9 Miehsler W, Reinisch W, Valic E. et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004; 53: 542-548.
• 10 Alikhan R, Cohen AT, Combe S. et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
• 11 Matta F, Singala R, Yaekoub AY. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
• 12 Bernstein CN, Blanchard JF, Houston DS. et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434.
• 13 Huerta C, Johansson S, Wallander M-A. et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943.
• 14 Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-2280.
• 15 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 616-617.
• 16 Novacek G, Weltermann A, Sobala A. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787 787.e771.
• 17 Ludvigsson JF, Welander A, Lassila R. et al. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br J Haematol 2007; 139: 121-127.
• 18 Crawshaw AP, Wotton CJ, Yeates DGR. et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66: 447-448.
• 19 Stassen PM, Derks RPH, Kallenberg CGM. et al. Venous thromboembolism in ANCA-associated vasculitis – Incidence and risk factors. Rheumatology 2008; 47: 530-534.
• 20 Merkel PA, Lo GH, Holbrook JT. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142: 620-626.
• 21 Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55: 146-149.
• 22 Sullivan PS, Dworkin MS, Jones JL. et al. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14: 321-324.
• 23 Fultz SL, McGinnis KA, Skanderson M. et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116: 420-423.
• 24 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699.
• 25 White RH, Zhou H, Murin S. et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
• 26 White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
• 27 Lijfering WM, Kate MK, Sprenger HG. et al. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006; 04: 1928-1930.
• 28 Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008; 336: 402-406.
• 29 Malek J, Rogers R, Kufera J. et al. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2010; Am J Emerg Med 2011; 29: 278-282.
• 30 Lijfering WM, de Vries APJ, Veeger NJGM. et al. Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. Thromb Haemost 2008; 99: 127-132.
• 31 Atzmony L, Halutz O, Avidor B. et al. Incidence of cytomegalovirus-associated thrombosis and its risk factors: a case-control study. Thromb Res 2010; 126: e439-443.
• 32 Tichelaar VYIG, Sprenger HG, Mäkelburg ABU. et al. Active cytomegalovirus infection in patients with acute venous thrombosis: A case-control study. Am J Hematol 2011; 86: 510-512.
• 33 van Wissen M, Keller TT, Ronkes B. et al. Influenza infection and risk of acute pulmonary embolism. Thromb J 2007; 05: 16.
• 34 Zhu T, Carcaillon L, Martinez I. et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb Haemost 2009; 102: 1259-1264.
• 35 Lozinguez O, Arnaud E, Belec L. et al. Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. Thromb-Haemost 2000; 83: 887-891.
• 36 Koster T, Rosendaal FRDD. et al. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. Lancet 2000; 355: 1694-1695.
• 37 Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51: 228-235.
• 38 Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22: 2064-2070.
• 39 Farrington P, Pugh S, Colville A. et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-569.
• 40 Smeeth L, Cook C, Thomas S. et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
• 41 Gangireddy C, Rectenwald JR, Upchurch GR. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45: 335-342.
• 42 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
• 43 Cimminiello C, Filippi A, Mazzaglia G. et al. Venous thromboembolism in medical patients treated in the setting of primary care: A nationwide case-control study in Italy. Thromb Res 2010; 126: 367-372.
• 44 Tichelaar YIGV, Knol HM, Mulder AB. et al. Association between deep vein thrombosis and transient inflammatory signs and symptoms: a case-control study. J Thromb Haemost 2010; 08: 1874-1876.
• 45 Bhagat K, Moss R, Collier J. et al. Endothelial „stunning“ following a brief exposure to endotoxin: a mechanism to link infection and infarction?. Cardiovasc Res 1996; 32: 822-829.
• 46 Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
• 47 Hooper WC, Phillips DJ, Ribeiro MJ. et al. Tumor necrosis factor-alpha downregulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 1994; 84: 483-489.
• 48 Johnson K, Aarden L, Choi Y. et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
• 49 Riewald M, Ruf W. Science review: role of coagulation protease cascades in sepsis. Crit Care 2003; 07: 123-129.
• 50 van Aken BE, den Heijer M, Bos GM. et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83: 536-539.
• 51 van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116: 173-177.
• 52 van Deventer SJ, Büller HR, ten Cate JW. et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.
• 53 Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
• 54 Levi M, Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
• 55 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
• 56 Hein TW, Singh U, Vasquez-Vivar J. et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206: 61-68.
• 57 Müller MM, Griesmacher A. Markers of endothelial dysfunction. Clin Chem Lab Med 2000; 38: 77-85.
• 58 Stouthard JM, Levi M, Hack CE. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742.
• 59 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
• 60 Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
• 61 Szalai AJ, Agrawal A, Greenhough TJ. et al. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999; 37: 265-270.
• 62 Bisoendial RJ, Kastelein JJP, Levels JHM. et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
• 63 Chen C, Nan B, Lin P. et al. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res 2008; 122: 125-133.
• 64 Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221.
• 65 Molins B, Peña E, Vilahur G. et al. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-2246.
• 66 Wu J, Stevenson MJ, Brown JM. et al. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 2008; 28: 698-704.